Philadelphia Chromosome Clinical Trials in Chicago, Illinois
4 recruitingChicago, Illinois
Showing 1–4 of 4 trials
Recruiting
Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
Recurrent B Acute Lymphoblastic LeukemiaB Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeRefractory B Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)84 enrolled276 locationsNCT03739814
Recruiting
Phase 2
Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Lymphoblastic LymphomaB Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
City of Hope Medical Center53 enrolled8 locationsNCT06918431
Recruiting
Phase 1
ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
B-cell Acute Lymphoblastic LeukemiaChronic Myeloid Leukemia (CML) in Lymphoid Blast CrisisPhiladelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL
Marlise Luskin, MD40 enrolled4 locationsNCT03595917
Recruiting
Not Applicable
Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL)
B-ALLB-cell Acute Lymphoblastic Leukemia (B-ALL)Philadelphia Chromosome Negative
University of Chicago20 enrolled1 locationNCT06785324